Back to Search
Start Over
A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation.
- Source :
-
Blood [Blood] 2000 Jul 01; Vol. 96 (1), pp. 80-5. - Publication Year :
- 2000
-
Abstract
- Blood stem cell transplantation (BSCT) results in rapid hematopoietic recovery in both the allogeneic and autologous transplant settings. Because of the large numbers of progenitor cells in mobilized blood, the administration of growth factors after transplantation may not provide further acceleration of hematopoietic recovery. A randomized, double-blind, placebo-controlled study was performed to determine the effects of filgrastim (granulocyte colony-stimulating factor; G-CSF) administration on hematopoietic recovery after allogeneic BSCT. Fifty-four patients with hematologic malignancies undergoing a related, HLA-matched allogeneic BSCT were randomly assigned to receive daily filgrastim at 10 microg/kg or placebo starting on the day of transplantation. A minimum of 3 x 10(6) CD34(+) cells/kg in the allograft was required for transplantation. All patients received a standard preparative regimen and a standard regimen for the prevention of graft-versus-host disease (GVHD). The median time to achieve an absolute neutrophil count greater than 0.5 x 10(9)/L was 11 days (range, 9-20 days) for patients who received filgrastim compared with 15 days (range, 10-22 days) for patients who received placebo (P =.0082). The median time to achieve a platelet count greater than 20 x 10(9)/L was 13 days (range, 8-35 days) for patients who received filgrastim compared with 15.5 days (range, 8-42 days) for patients who received placebo (P =.79). There were no significant differences for red blood cell transfusion independence, the incidence of acute GVHD, or 100-day mortality between the groups. The administration of filgrastim appears to be a safe and effective supportive-care measure following allogeneic BSCT.
- Subjects :
- Adolescent
Adult
Aged
Double-Blind Method
Female
Filgrastim
Graft vs Host Disease prevention & control
Hematopoiesis drug effects
Humans
Leukemia blood
Leukemia mortality
Leukocyte Count drug effects
Lymphoma, Non-Hodgkin blood
Lymphoma, Non-Hodgkin mortality
Male
Middle Aged
Multiple Myeloma blood
Multiple Myeloma mortality
Neutrophils
Placebos
Platelet Count drug effects
Recombinant Proteins
Survival Rate
Time Factors
Transplantation, Homologous
Treatment Outcome
Granulocyte Colony-Stimulating Factor therapeutic use
Hematopoietic Stem Cell Transplantation
Leukemia therapy
Lymphoma, Non-Hodgkin therapy
Multiple Myeloma therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0006-4971
- Volume :
- 96
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Blood
- Publication Type :
- Academic Journal
- Accession number :
- 10891434